NCT07210151 Anatomical Navigation for Guided Electrophysiology in AFL and AFib
| NCT ID | NCT07210151 |
| Status | Recruiting |
| Phase | — |
| Sponsor | LUMA Vision Ltd. |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-01-29 |
| Primary Completion | 2026-12-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-01-29 with a primary completion date of 2026-12-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to collect data on the use of the VERAFEYE Anatomical Guidance System in adult patients indicated to undergo a catheter ablation procedure for the treatment of Atrial Flutter (AFL), paroxysmal AF (PAF) or persistent AF (perAF). The study will collect specific information on management of AFL/AF ablation procedures with the commercial VERAFEYE Anatomical Guidance System including but not limited to acute procedural success , and how the VERAFEYE Anatomical Guidance System is used overall. Results from this study may be used to guide development and refinement the VERAFEYE Anatomical Guidance System.
Eligibility Criteria
Inclusion Criteria: * IC1: Subject is at least 18 years of age at the time of consent * IC2: Subject is scheduled to undergo a catheter-ablation procedure to treat AFL/AF (\*according to current international and local guidelines and per physician discretion) * IC3: Subject is able to understand and willing to provide written informed consent * IC4: Subject is able and willing to complete all study assessments associated with this clinical study at an approved clinical study site Exclusion Criteria: * EC1: Subject where placement of VERAFEYE Imaging Catheter is technically not feasible per physician discretion * EC2: Pregnant women or women who plan to become pregnant during the course of their participation in the study (women should either be of non- childbearing potential at the time of enrolment (as documented in the medical file) or have a negative pregnancy test within the previous 7 days prior to the procedure) * EC3: Unrecovered/unresolved Adverse Events from any previous invasive procedure * EC4: Any planned surgical or endovascular intervention within 30 days before or after the ablation procedure. * EC5: Life expectancy less than 12 months * EC6: Current LA thrombus Note: Screening for LA thrombus is required to be performed within 48 hours prior to or during the index procedure. Method of screening per physician discretion. If an atrial thrombus is observed prior to or during the planned index procedure, the index procedure will not begin or will be terminated before accessing the left atrium, and no ablation will be performed. The index procedure for this subject may be rescheduled to be performed within 30 days post ICF signature, provided that the thrombus is no longer present.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07210151 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07210151 currently recruiting?
Yes, NCT07210151 is actively recruiting participants. Contact the research team at alisa.komleva@lumavision.com for enrollment information.
Where is the NCT07210151 trial being conducted?
This trial is being conducted at Split, Croatia, Prague, Czechia, Prague, Czechia, Vilnius, Lithuania.
Who is sponsoring the NCT07210151 clinical trial?
NCT07210151 is sponsored by LUMA Vision Ltd.. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.